Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using minoxidil foam and a dermaroller for three months to combat hair loss, with noticeable progress. They are seeking finasteride but face difficulties obtaining it in Germany.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

Hair loss treatments discussed include Minoxidil, finasteride, and RU58841. Concerns were raised about delays in product presentations and business strategies.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

The user is experiencing chronic folliculitis with scalp sores and is concerned about a receding hairline. They have tried various treatments including antibiotics, Nizoral 2% shampoo, and lifestyle changes, but are seeking further advice.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

Hair loss discussion includes PRP and exosomes treatments. Questioning effectiveness and ideal candidate for these treatments.

RU58841 may cause heart-related side effects like palpitations and chest pain, though evidence is mostly anecdotal. Users report mixed experiences, with some stopping due to side effects and others using it without issues, but concerns about its safety and sourcing remain.

RU58841 is discussed as a treatment that stops scalp itching when used with finasteride or dutasteride. The user is considering trying RU58841 due to persistent itching despite using the "big 3" treatments.

The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.

Transitioning from finasteride to Pyrilutamide as a treatment for hair loss, and the potential risks associated with taking such a drug. People have discussed the need to wait at least 6 months in order to assess results, and are willing to risk their health trying this new medication.

The conversation discusses hair loss treatments, specifically mentioning Spiro, Min, Fin, and RU. It highlights that Spiro is generally for women and can affect men's hormonal balance.

User Solid_Repeat5382 shared their experience with Pyrilutamide for hair loss, which initially reduced shedding but later lost effectiveness. They plan to switch back to RU58841 and finasteride, while continuing minoxidil and dermapen treatments.

Fatty liver and related issues may influence hair loss conditions like Dupa/Aga. Treatments discussed include Minoxidil, finasteride, RU58841, myo-inositol, and L-glutamine.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The user switched from finasteride to 2.5 mg dutasteride daily and added 1% pyrilutamide to address persistent scalp itch, but the itch remains. They also use 2% ketoconazole and 2.5% selenium sulfide shampoo for temporary relief.

A potential new treatment for hair loss, Pyrilutamide, and the discussion of whether or not people should still be taking traditional treatments like Minoxidil and Finasteride with it.

Discouragement regarding Pyrilutamide, a drug in development for hair loss, and the potential side effects of Finasteride. People discussed anecdotal experiences with Pyrilutamide as well as suggestions to wait out Phase 3 trials before making any conclusions.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

RU58841, oral and topical minoxidil, finasteride, and ketoconazole shampoo led to significant hair regrowth, though some suspect a hair transplant. Concerns about RU58841's side effects, like anxiety and heart issues, were discussed.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

The user completed a Clascoterone study with no observable changes in hair loss and plans to try microneedling and Minoxidil next. They will microneedle weekly and apply Minoxidil twice daily, except on the night of microneedling, and compare results after six months.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

RU58841 is used for hair loss, with some users reporting decreased shedding and preserved hairlines. Concerns about safety and side effects like heart issues are noted, and some combine it with finasteride and minoxidil for better results.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.

Breezula passed a clinical trial in August and there are questions about its availability in 2021 and potential delays due to Covid. No specific treatments were discussed.

The user changed their hair loss treatment in October/November, experienced increased shedding, and now sees no new hair growth, with a worsening condition and a possible bald spot. They also have severe seborrheic dermatitis, which may be affecting their scalp and hair loss.